<DOC>
	<DOCNO>NCT01230970</DOCNO>
	<brief_summary>This trial assess intratumoural pharmacological activity BN83495 change intratumoural level sex hormone associate inhibition steroid sulphatase ( STS ) activity .</brief_summary>
	<brief_title>Exploratory Study Assess Short Term Intratumoural Peripheral Effects BN83495 Postmenopausal Women With Newly Diagnosed Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Female subject 55 80 year histologically cytologically document primary intraductal lobular invasive breast cancer meet follow criterion : T2 , N0 N1 , M0 . Primary tumour clinically determine 2 5 cm great dimension . Laboratory documentation positive oestrogen receptor ( ER+ ) status least 10 % tumour cell . Laboratory documentation HER2 negative status . Postmenopausal define spontaneous menses total 2 year amenorrheic least 12 month serum oestrogen level &lt; 30 pg/mL , luteinising hormone ( LH ) /follicle stimulate hormone ( FSH ) &gt; 20 IU/L , chemotherapyinduced amenorrhoea least 12 month bilateral oophorectomy , radiation castration amenorrhoeic least 3 month . Eastern Cooperative Oncology Group ( ECOG ) performance status â‰¤2 . Has locally advance breast cancer consider nonoperable without neoadjuvant therapy . Has evidence metastatic disease diagnosis inflammatory breast cancer Has ductal carcinoma situ</criteria>
	<gender>Female</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>